small molecule

DAYBUE

TROFINETIDE

Loss of exclusivityJanuary 2043latest FDA-listed patent expiry

CompanyAcadia Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	DAYBUE
Active ingredient	TROFINETIDE
Strength	200MG/ML
Dosage form	SOLUTION
Route	ORAL
Modality	Small molecule
FDA approval	March 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
12492167*PED	January 2043	—
11827600*PED	January 2043	—
12492167	July 2042	substance, product
11827600	July 2042	substance, product
11370755*PED	February 2041	—
11370755	August 2040	substance, product
9212204*PED	July 2032	—
9212204	January 2032	use U-3556

Regulatory exclusivity

Code	Expires
PED	September 2030
ODE-425	March 2030
PED	September 2028
NCE	March 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Acadia Pharmaceuticals